Outcomes and objectives The primary objective was to compare the efficacy of 68 weeks of subcutaneous semaglutide 2.4 mg weekly versus placebo administration, as an adjunct to diet and exercise, on %WL in participants with less than 20% weight loss after primary GB or SG at the end of 68 weeks of treatment
Slows gastric emptying, keeping food in the stomach longer and prolonging fullness
Common examples include certain antidepressants, antipsychotics, corticosteroids, beta-blockers, insulin, and some antiepileptics
Ultimately, semaglutide can be a powerful tool in your weight loss journey if it fits your health profile and goals
Significant Weight Loss: At this stage, many individuals may experience more substantial weight loss
Just never lose track of which vial received how much water